Fluticasone Furoate vs fluticasone propionate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: Glucocorticoid receptor · full Asthma pipeline

Fluticasone Furoate · Arnuity Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule (corticosteroid)
Partial signal

NCT00603382 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled trial with about 95 to 110 people per group. Its primary lung-function comparison (trough FEV1) was significant for the 50, 100 and 200 microgram doses but not for the lowest 25 microgram dose, so the primary result is mixed across the doses tested.

Reported efficacy

Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409) (met)

Result source: NCT00603278

fluticasone propionate

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT07664527 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFluticasone Furoatefluticasone propionate
Severe exacerbations, annualised rate—Trial running · NCT046517771.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
1 other result
  • 2.6 vs 2.7 250/50 mcg BID · wk 52 · n 310 · Phase 4 · secondary NCT00452348
Trough FEV1, change0.2 vs 0.0+0.1 vs placebo100 µg OD · wk 24 · n 111NCT01159912
19 other results
  • 0.4 vs 0.2 100/25 µg OD · wk 12 · n 200 · Phase 3 · primary NCT01165138
  • 0.2 vs 0.0 50 µg OD · wk 12 · n 108 · Phase 3 · primary NCT01436071
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.2 vs -0.1 200 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 200 µg OD · wk 8 · n 99 · Phase 2 · primary NCT00603746
  • 0.1 vs -0.1 100 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 800 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.0 600 µg OD · wk 8 · n 107 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 400 µg OD · wk 8 · n 97 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 400 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 300 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
0.2 vs 0.1+0.2 vs placebo100 mcg · wk 12 · n 129NCT02139644
25 other results
  • 0.2 vs 0.1 50 mcg · wk 12 · n 128 · Phase 3 · primary NCT02139644
  • 0.1 vs 0.0 200 mcg · wk 26 · n 120 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · primary NCT01576718
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · primary NCT01576718
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · secondary NCT01576718
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · secondary NCT01576718
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767
ACQ-5, change—Trial running · NCT04651777—Not posted · NCT00158834
OCS dose reduction—Trial running · NCT04651777—Not posted · NCT00158834

Severe exacerbations, annualised rate

Fluticasone Furoate
—Trial running · NCT04651777
fluticasone propionate
1.9 vs 2.1vs Fluticasone Propionate250/50 mcg BID · wk 52 · n 306NCT00452699
1 other result
  • 2.6 vs 2.7 250/50 mcg BID · wk 52 · n 310 · Phase 4 · secondary NCT00452348

Trough FEV1, change

Fluticasone Furoate
0.2 vs 0.0+0.1 vs placebo100 µg OD · wk 24 · n 111NCT01159912
19 other results
  • 0.4 vs 0.2 100/25 µg OD · wk 12 · n 200 · Phase 3 · primary NCT01165138
  • 0.2 vs 0.0 50 µg OD · wk 12 · n 108 · Phase 3 · primary NCT01436071
  • 0.4 vs 0.2 200/25 µg OD · wk 24 · n 187 · Phase 3 · primary NCT01134042
  • 0.5 vs 0.4 200/25 µg OD · wk 12 · n 337 · Phase 3 · secondary NCT01686633
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.4 vs 0.4 100/25 µg OD · wk 12 · n 334 · Phase 3 · secondary NCT01686633
  • 0.3 vs 0.3 100/25 µg · wk 36 · n 926 · Phase 3 · secondary NCT01086384
  • 0.2 vs -0.1 200 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 200 µg OD · wk 8 · n 99 · Phase 2 · primary NCT00603746
  • 0.1 vs -0.1 100 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 800 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.0 600 µg OD · wk 8 · n 107 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 400 µg OD · wk 8 · n 97 · Phase 2 · primary NCT00603278
  • 0.2 vs -0.0 400 µg OD · wk 8 · n 101 · Phase 2 · primary NCT00603746
  • 0.2 vs -0.1 300 µg OD · wk 8 · n 102 · Phase 2 · primary NCT00603278
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • -0.5 vs -0.8 100/25 µg OD · wk 4.14 · n 46 · Phase 2 · secondary NCT01128569
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
fluticasone propionate
0.2 vs 0.1+0.2 vs placebo100 mcg · wk 12 · n 129NCT02139644
25 other results
  • 0.2 vs 0.1 50 mcg · wk 12 · n 128 · Phase 3 · primary NCT02139644
  • 0.1 vs 0.0 200 mcg · wk 26 · n 120 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 200/12.5 mcg · wk 26 · n 130 · Phase 3 · secondary NCT02175771
  • -0.1 vs -0.1 100 mcg once daily · wk 20 · n 122 · Phase 3 · secondary NCT02094937
  • 0.1 vs 0.0 100 mcg · wk 26 · n 123 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.0 100/12.5 mcg · wk 26 · n 119 · Phase 3 · secondary NCT02175771
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · primary NCT01576718
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · primary NCT01576718
  • 0.3 vs 0.1 100 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 50 mcg · wk 12 · n 100 · Phase 2 · primary NCT01479621
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · primary NCT01576718
  • 0.2 vs 0.1 25 mcg · wk 12 · n 97 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 12.5 mcg · wk 12 · n 94 · Phase 2 · primary NCT01479621
  • 0.2 vs 0.1 250/50 mcg BID · wk 52 · n 303 · Phase 4 · primary NCT00452348
  • 0.1 vs 0.1 200 mcg · wk 12 · n 97 · Phase 2 · secondary NCT01576718
  • 0.2 vs 0.1 100 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 100 mcg · wk 12 · n 102 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 50 µg OD · wk 12 · n 112 · Phase 2 · secondary NCT01563029
  • 0.1 vs 0.1 50 mcg · wk 12 · n 104 · Phase 2 · secondary NCT01576718
  • 0.1 vs 0.1 400 mcg · wk 12 · n 103 · Phase 2 · secondary NCT01576718
  • 0.3 vs 0.1 25 µg OD · wk 12 · n 96 · Phase 2 · secondary NCT01563029
  • 0.2 vs 0.2 25 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 12.5 µg OD · wk 4 · n 86 · Phase 2 · secondary NCT01573767
  • 0.2 vs 0.2 6.25 µg OD · wk 4 · n 83 · Phase 2 · secondary NCT01573767

ACQ-5, change

Fluticasone Furoate
—Trial running · NCT04651777
fluticasone propionate
—Not posted · NCT00158834

OCS dose reduction

Fluticasone Furoate
—Trial running · NCT04651777
fluticasone propionate
—Not posted · NCT00158834
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety

Coverage. Fluticasone Furoate: 16 of 16 rows · fluticasone propionate: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFluticasone Furoate
Rows use multiple source trials
fluticasone propionate
Rows use multiple source trials
ACT Control
responder rate · % of participants
99.1% (n=112) vs 97.4% (n=114) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
99.1% (n=112) vs 97.4% (n=114) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
ACT Total
absolute change · score
-0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
-0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
Evening PEF
absolute change · L/min
31.3 vs 9.6 placebo L/min200 µg ODc,d,b,e
NCT00603382 · Phase 2
show 3 more doses
25.7 vs 9.6 placebo L/min100 µg OD
NCT00603382 · Phase 2
30.3 vs 9.6 placebo L/min50 µg OD
NCT00603382 · Phase 2
23.6 vs 9.6 placebo L/min25 µg OD
NCT00603382 · Phase 2
13.5 vs 5.1 placebo L/min @ 12wk100 µg ODc,d,b,e
NCT01563029 · Phase 2 · registry result, not featured evidence
show 5 more doses
11 vs 5 placebo L/min @ 12wk100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
18.5 vs 5.1 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
18.2 vs 5 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
16.3 vs 5.1 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
16.2 vs 5 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
Evening PEF
absolute change · L
24.9 vs 7.6 placebo L50 µg ODf,a,b,e
NCT01436110 · Phase 3 · registry result, not featured evidence
1 other source trial
22.8 vs 19.5 placebo L @ 12wk50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
7.45 vs 3.42 placebo L @ 12wk200 mcgc,f,a,b,e
NCT01576718 · Phase 2 · registry result, not featured evidence
show 7 more doses
7.89 vs 3.35 placebo L @ 12wk200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
6.41 vs 3.42 placebo L @ 12wk100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
6.52 vs 3.35 placebo L @ 12wk100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
3.81 vs 3.42 placebo L @ 12wk50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
4.22 vs 3.35 placebo L @ 12wk50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
10.97 vs 3.42 placebo L @ 12wk400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
11.72 vs 3.35 placebo L @ 12wk400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
FEV1
absolute change · L
-0.227 vs -0.372 placebo L @ 4.14wk100/25 µg ODg,a,b,h
NCT01128569 · Phase 2 · registry result, not featured evidence
0.2 vs 0.09 Fluticasone Propionate L @ 52wk250/50 mcg BIDg,a,b,h
NCT00452699 · Phase 4 · registry result, not featured evidence
Morning PEF
absolute change · L/min
35.6 vs 13.6 placebo L/min200 µg ODc,d,b,e
NCT00603382 · Phase 2
show 3 more doses
29.5 vs 13.6 placebo L/min100 µg OD
NCT00603382 · Phase 2
33.5 vs 13.6 placebo L/min50 µg OD
NCT00603382 · Phase 2
27.2 vs 13.6 placebo L/min25 µg OD
NCT00603382 · Phase 2
15.8 vs 3.3 placebo L/min @ 12wk100 µg ODc,d,b,e
NCT01563029 · Phase 2 · registry result, not featured evidence
show 5 more doses
14.2 vs 2.7 placebo L/min @ 12wk100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
22.8 vs 3.3 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
20.6 vs 2.7 placebo L/min @ 12wk50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
21.9 vs 3.3 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
23.3 vs 2.7 placebo L/min @ 12wk25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
Poorly-controlled Asthma Withdrawal
responder rate · % of participants
4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
Rescue-free 24 h Periods
absolute change · percentage points
-0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
-0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
Rescue-free 24-h Period
percent change · % of baseline
32% (n=95) vs 21.9% (n=94) placebo200 µg ODc,i,a,b,e
NCT00603382 · Phase 2
show 3 more doses
40.8% (n=110) vs 21.9% (n=94) placebo100 µg OD
NCT00603382 · Phase 2
34.5% (n=98) vs 21.9% (n=94) placebo50 µg OD
NCT00603382 · Phase 2
29.3% (n=96) vs 21.9% (n=94) placebo25 µg OD
NCT00603382 · Phase 2
-3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailyi,a,b,e
NCT02301975 · Phase 3 · registry result, not featured evidence
Symptom-free 24 h Periods
absolute change · percentage points
-1% (n=122) vs -1.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
1 other source trial
25.1% (n=116) vs 16.8% (n=114) placebo50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
-1% (n=122) vs -1.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
Symptom-free 24-h Period
percent change · % of baseline
31.7% (n=95) vs 18.4% (n=94) placebo200 µg ODc,a,b,e
NCT00603382 · Phase 2
show 3 more doses
38.7% (n=110) vs 18.4% (n=94) placebo100 µg OD
NCT00603382 · Phase 2
31.1% (n=98) vs 18.4% (n=94) placebo50 µg OD
NCT00603382 · Phase 2
25.3% (n=96) vs 18.4% (n=94) placebo25 µg OD
NCT00603382 · Phase 2
19.7% (n=110) vs 9.9% (n=113) placebo @ 4wk25 µg ODc,a,b,e
NCT01573767 · Phase 2 · registry result, not featured evidence
show 2 more doses
18.3% (n=112) vs 9.9% (n=113) placebo @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
10.1% (n=113) vs 9.9% (n=113) placebo @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
Well Controlled Asthma
responder rate · % of participants
89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b
NCT02094937 · Phase 3 · registry result, not featured evidence
Dropout rate
9.5%200 µg ODj
NCT00603382 · Phase 2
show 41 more results
10.9%100 µg OD
NCT00603382 · Phase 2
9%50 µg OD
NCT00603382 · Phase 2
14.4%25 µg OD
NCT00603382 · Phase 2
13.9%200 µg OD
NCT00603278 · Phase 2
16.2%100 µg OD
NCT00603278 · Phase 2
13.1%400 µg OD
NCT00603278 · Phase 2
10.7%300 µg OD
NCT00603278 · Phase 2
18.2%200 µg OD
NCT00603746 · Phase 2
16.7%800 µg OD
NCT00603746 · Phase 2
12.1%600 µg OD
NCT00603746 · Phase 2
7.9%400 µg OD
NCT00603746 · Phase 2
19.3%100 µg OD
NCT01159912 · Phase 3
10.9%100/25 µg OD
NCT01165138 · Phase 3
12.6%200 µg OD
NCT01431950 · Phase 3
16%100 µg OD
NCT01431950 · Phase 3
14.2%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
28%100 µg OD
NCT01563029 · Phase 2
27.5%50 µg OD
NCT01563029 · Phase 2
20.3%25 µg OD
NCT01563029 · Phase 2
13.9%50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
7.2%200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
9.2%100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
22.2%50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
11.3%50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
—100/25 µg
NCT01086384 · Phase 3 · registry result, not featured evidence
—200/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
—100/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
1.8%200/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
3.6%100/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
—100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—100 µg
NCT01332292 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
—200 µg OD
NCT00766090 · Phase 2 · registry result, not featured evidence
—100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
—100/25 µg QDk
NCT02730351 · Phase 4 · registry result, not featured evidence
show 41 more results
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
53.1%Asthmatic Smoker Treated With Mont
NCT00712335 · Phase 4 · registry result, not featured evidence
37.5%Asthmatic Smokers Treated With Com
NCT00712335 · Phase 4 · registry result, not featured evidence · combination
26.5%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
25.5%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
2.8%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
6.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
28%100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
27.5%50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
20.3%25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
21.1%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12.4%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
18.4%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
1.1%200 µg ODj
NCT00603382 · Phase 2
show 41 more results
1.8%100 µg OD
NCT00603382 · Phase 2
1%50 µg OD
NCT00603382 · Phase 2
1%25 µg OD
NCT00603382 · Phase 2
1%200 µg OD
NCT00603278 · Phase 2
2.9%100 µg OD
NCT00603278 · Phase 2
2%400 µg OD
NCT00603278 · Phase 2
0%300 µg OD
NCT00603278 · Phase 2
3%200 µg OD
NCT00603746 · Phase 2
0%800 µg OD
NCT00603746 · Phase 2
0.9%600 µg OD
NCT00603746 · Phase 2
0%400 µg OD
NCT00603746 · Phase 2
1.8%100 µg OD
NCT01159912 · Phase 3
1%100/25 µg OD
NCT01165138 · Phase 3
1.7%200 µg OD
NCT01431950 · Phase 3
1.7%100 µg OD
NCT01431950 · Phase 3
3.6%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
1.7%100 µg OD
NCT01563029 · Phase 2
0.8%50 µg OD
NCT01563029 · Phase 2
0%25 µg OD
NCT01563029 · Phase 2
—50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
—
NCT02502734 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
0.9%200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
0.9%100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
0.9%50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
0%50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
—100/25 µg
NCT01086384 · Phase 3 · registry result, not featured evidence
—200/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
—100/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
0%200/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
0%100/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
—100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
—100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
—100 µg
NCT01332292 · Phase 2 · registry result, not featured evidence
—100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
—200 µg OD
NCT00766090 · Phase 2 · registry result, not featured evidence
—100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
—100/25 µg QDk
NCT02730351 · Phase 4 · registry result, not featured evidence
show 41 more results
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
—Asthmatic Smoker Treated With Mont
NCT00712335 · Phase 4 · registry result, not featured evidence
—Asthmatic Smokers Treated With Com
NCT00712335 · Phase 4 · registry result, not featured evidence · combination
3.3%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
1.9%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
—50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
—100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
—50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
1.6%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
—100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
—200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
—100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
1.7%100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0.8%50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0%25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0.9%25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
—100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
—12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Serious AEs
0%200 µg ODj
NCT00603382 · Phase 2
show 41 more results
0.9%100 µg OD
NCT00603382 · Phase 2
0%50 µg OD
NCT00603382 · Phase 2
1%25 µg OD
NCT00603382 · Phase 2
0%200 µg OD
NCT00603278 · Phase 2
0%100 µg OD
NCT00603278 · Phase 2
1%400 µg OD
NCT00603278 · Phase 2
1%300 µg OD
NCT00603278 · Phase 2
2%200 µg OD
NCT00603746 · Phase 2
0%800 µg OD
NCT00603746 · Phase 2
0.9%600 µg OD
NCT00603746 · Phase 2
0%400 µg OD
NCT00603746 · Phase 2
3.5%100 µg OD
NCT01159912 · Phase 3
0%100/25 µg OD
NCT01165138 · Phase 3
3.4%200 µg OD
NCT01431950 · Phase 3
2.5%100 µg OD
NCT01431950 · Phase 3
3%200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.8%100 µg OD
NCT01563029 · Phase 2
0.8%50 µg OD
NCT01563029 · Phase 2
0%25 µg OD
NCT01563029 · Phase 2
2.5%50 mcg
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
0%
NCT02502734 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
0.3%200/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
1.2%100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
0%50 µg OD
NCT01436110 · Phase 3 · registry result, not featured evidence
0.8%50 µg OD
NCT01436071 · Phase 3 · registry result, not featured evidence
4.1%100/25 µg
NCT01086384 · Phase 3 · registry result, not featured evidence
0.5%200/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
1.5%100/25 µg OD
NCT01018186 · Phase 3 · registry result, not featured evidence
0%200/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
0%100/25 µg PM
NCT01086410 · Phase 3 · registry result, not featured evidence
0%100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
0%100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
0%100 µg/25 µg
NCT01453023 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128595 · Phase 2 · registry result, not featured evidence
0%100 µg
NCT01332292 · Phase 2 · registry result, not featured evidence
0%100/25 µg OD
NCT01128569 · Phase 2 · registry result, not featured evidence
0%200 µg OD
NCT00766090 · Phase 2 · registry result, not featured evidence
0%100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
1.4%100/25 µg QDk
NCT02730351 · Phase 4 · registry result, not featured evidence
show 41 more results
0%50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 1.5 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 3 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%50 ug, 6 um
NCT00692978 · Phase 4 · registry result, not featured evidence
0%Asthmatic Smoker Treated With Mont
NCT00712335 · Phase 4 · registry result, not featured evidence
0%Asthmatic Smokers Treated With Com
NCT00712335 · Phase 4 · registry result, not featured evidence · combination
4.6%250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
2.3%250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
2%50/100 mcg BD
NCT00353873 · Phase 4 · registry result, not featured evidence
0%100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
1.9%50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
1.2%100/25 mcg Once Daily
NCT02301975 · Phase 3 · registry result, not featured evidence
0.8%100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
0%50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
—100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0.8%100 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence
0%100/25 mcg once daily
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
9.8%200/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
6.4%200 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5%100/12.5 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
5.5%100 mcg
NCT02175771 · Phase 3 · registry result, not featured evidence
0.6%100/50 HFA
NCT00441441 · Phase 3 · registry result, not featured evidence
0.8%100 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0.8%50 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
0%25 µg OD
NCT01563029 · Phase 2 · registry result, not featured evidence
—25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
—6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%12.5 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0%6.25 OD
NCT01573767 · Phase 2 · registry result, not featured evidence
0.9%200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
0.9%100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
0.9%50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
0%400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
1.9%100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
1%50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
0%12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
200 µg ODj
headache 5.3% (placebo 10.6%)
nasopharyngitis 3.2% (placebo 1.1%)
oropharyngitis 3.2% (placebo 1.1%)
NCT00603382 · Phase 2
show 40 more results
100 µg OD
headache 10.9% (placebo 10.6%)
nasopharyngitis 3.6% (placebo 1.1%)
oropharyngitis 3.6% (placebo 1.1%)
NCT00603382 · Phase 2
50 µg OD
headache 6% (placebo 10.6%)
back pain 3% (placebo 0%)
oropharyngitis 1% (placebo 1.1%)
NCT00603382 · Phase 2
25 µg OD
headache 6.2% (placebo 10.6%)
back pain 0% (placebo 0%)
nasopharyngitis 0% (placebo 1.1%)
NCT00603382 · Phase 2
200 µg OD
headache 7.9% (placebo 5.6%)
nasopharyngitis 5% (placebo 7.5%)
upper respiratory tract infection 3% (placebo 2.8%)
NCT00603278 · Phase 2
100 µg OD
headache 8.6% (placebo 5.6%)
nasopharyngitis 8.6% (placebo 7.5%)
diarrhoea 3.8% (placebo 0%)
NCT00603278 · Phase 2
400 µg OD
headache 9.1% (placebo 5.6%)
cough 4% (placebo 0.9%)
nasopharyngitis 4% (placebo 7.5%)
NCT00603278 · Phase 2
300 µg OD
headache 7.8% (placebo 5.6%)
nasopharyngitis 6.8% (placebo 7.5%)
back pain 2.9% (placebo 0%)
NCT00603278 · Phase 2
200 µg OD
dysphonia 4% (placebo 1%)
oropharyngeal candidiasis 4% (placebo 1%)
headache 3% (placebo 9.7%)
NCT00603746 · Phase 2
800 µg OD
headache 9.8% (placebo 9.7%)
nasopharyngitis 6.9% (placebo 3.9%)
oral candidiasis 6.9% (placebo 0%)
NCT00603746 · Phase 2
600 µg OD
headache 11.2% (placebo 9.7%)
back pain 3.7% (placebo 1%)
pharyngolaryngeal pain 2.8% (placebo 1%)
NCT00603746 · Phase 2
400 µg OD
headache 9.9% (placebo 9.7%)
dysphonia 5% (placebo 1%)
nasopharyngitis 5% (placebo 3.9%)
NCT00603746 · Phase 2
100 µg OD
nasopharyngitis 7.9% (placebo 5.2%)
bronchitis 7% (placebo 6.1%)
headache 6.1% (placebo 4.3%)
NCT01159912 · Phase 3
100/25 µg OD
nasopharyngitis 10% (placebo 7.4%)
headache 5% (placebo 3.9%)
NCT01165138 · Phase 3
200 µg OD
headache 12.6%
nasopharyngitis 12.6%
bronchitis 6.7%
NCT01431950 · Phase 3
100 µg OD
bronchitis 11.8%
nasopharyngitis 11.8%
headache 10.1%
NCT01431950 · Phase 3
200/25 µg OD
nasopharyngitis 12.7%
headache 5.6%
bronchitis 3.6%
NCT01134042 · Phase 3 · combination · Asthma · phase 3
100 µg OD
cough 8.5% (placebo 5%)
headache 5.9% (placebo 1.7%)
rhinorrhoea 5.1% (placebo 1.7%)
NCT01563029 · Phase 2
50 µg OD
pharyngitis 5.8% (placebo 3.4%)
bronchitis 3.3% (placebo 0.8%)
nasopharyngitis 3.3% (placebo 3.4%)
NCT01563029 · Phase 2
25 µg OD
nasopharyngitis 7.6% (placebo 3.4%)
cough 5.9% (placebo 5%)
oropharyngeal pain 5.1% (placebo 0.8%)
NCT01563029 · Phase 2
50 mcg
upper respiratory tract infection 12.2% (placebo 13.8%)
nasopharyngitis 9.7% (placebo 10.5%)
rhinitis 6.7% (placebo 7.5%)
NCT02889809 · Phase 4 · registry result, not featured evidence · background therapy
nasopharyngitis 6.9% (placebo 8.3%)
headache 5.2% (placebo 13.3%)
cough 3.4% (placebo 5%)
NCT02502734 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
200/25 µg OD
headache 8.4%
nasopharyngitis 7.2%
upper respiratory tract infection 2%
NCT01686633 · Phase 3 · registry result, not featured evidence
100/25 µg OD
headache 8.4%
nasopharyngitis 6.4%
upper respiratory tract infection 2.3%
NCT01686633 · Phase 3 · registry result, not featured evidence
50 µg OD
headache 14.5% (placebo 11.3%)
nasopharyngitis 6.8% (placebo 5.2%)
pharyngitis 6% (placebo 8.7%)
NCT01436110 · Phase 3 · registry result, not featured evidence
50 µg OD
nasopharyngitis 5.8% (placebo 4.1%)
headache 5% (placebo 11.6%)
pharyngitis 5% (placebo 5%)
NCT01436071 · Phase 3 · registry result, not featured evidence
100/25 µg
headache 18.6%
nasopharyngitis 15.4%
upper respiratory tract infection 7.2%
NCT01086384 · Phase 3 · registry result, not featured evidence
200/25 µg OD
headache 17.3%
upper respiratory tract infection 14.9%
nasopharyngitis 9.4%
NCT01018186 · Phase 3 · registry result, not featured evidence
100/25 µg OD
headache 19.4%
upper respiratory tract infection 16.9%
nasopharyngitis 12.4%
NCT01018186 · Phase 3 · registry result, not featured evidence
200/25 µg PM
headache 16.1% (placebo 8.6%)
back pain 3.6% (placebo 0%)
sinus headache 3.6% (placebo 0%)
NCT01086410 · Phase 3 · registry result, not featured evidence
100/25 µg PM
headache 26.8% (placebo 8.6%)
arthralgia 3.6% (placebo 0%)
nasopharyngitis 3.6% (placebo 1.7%)
NCT01086410 · Phase 3 · registry result, not featured evidence
100 µg AM
headache 52.2% (placebo 36%)
upper respiratory tract infection 26.1% (placebo 8%)
nasopharyngitis 8.7% (placebo 4%)
NCT01808339 · Phase 2 · registry result, not featured evidence
100 µg PM
headache 41.7% (placebo 36%)
viral upper respiratory tract infection 20.8% (placebo 8%)
dysmenorrhoea 8.3% (placebo 8%)
NCT01808339 · Phase 2 · registry result, not featured evidence
100 µg/25 µg
bronchitis 4%
conjunctivitis 4%
headache 4%
NCT01453023 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 55.6% (placebo 40.7%)
nasopharyngitis 11.1% (placebo 7.4%)
oropharyngeal pain 11.1% (placebo 7.4%)
NCT01128595 · Phase 2 · registry result, not featured evidence
100 µg
headache 11.5% (placebo 0%)
acute tonsillitis 3.8% (placebo 0%)
cough 3.8% (placebo 0%)
NCT01332292 · Phase 2 · registry result, not featured evidence
100/25 µg OD
headache 9.8% (placebo 17.6%)
dysphonia 3.9% (placebo 0%)
mouth ulceration 3.9% (placebo 0%)
NCT01128569 · Phase 2 · registry result, not featured evidence
200 µg OD
upper respiratory tract infection 5% (placebo 1.1%)
NCT00766090 · Phase 2 · registry result, not featured evidence
100 µg BID
upper respiratory tract infection 4.9% (placebo 1.1%)
NCT00766090 · Phase 2 · registry result, not featured evidence
100/25 µg QDk
upper respiratory tract infection 6.8%
NCT02730351 · Phase 4 · registry result, not featured evidence
show 29 more results
250/50 mcg BID
upper respiratory tract infection 20.3%
headache 18.3%
nasopharyngitis 17.6%
NCT00452699 · Phase 4 · registry result, not featured evidence
250/50 mcg BID
nasopharyngitis 17.4%
headache 16.5%
upper respiratory tract infection 14.5%
NCT00452348 · Phase 4 · registry result, not featured evidence
50/100 mcg BD
headache 18%
nasopharyngitis 9.3%
rhinitis 8%
NCT00353873 · Phase 4 · registry result, not featured evidence
100/50mcg BID
headache 3.2%
upper respiratory tract infection 3.2%
abdominal pain upper 2.4%
NCT00118716 · Phase 4 · registry result, not featured evidence
50/12.5 mcg BID
nasopharyngitis 4.3% (placebo 5.3%)
NCT02980133 · Phase 3 · registry result, not featured evidence
100/25 mcg Once Daily
nasopharyngitis 12.1%
headache 8.1%
bronchitis 4%
NCT02301975 · Phase 3 · registry result, not featured evidence
100 mcg
headache 7% (placebo 3.9%)
nasopharyngitis 7% (placebo 3.1%)
upper respiratory tract infection 3.1% (placebo 4.7%)
NCT02139644 · Phase 3 · registry result, not featured evidence
50 mcg
nasopharyngitis 5.4% (placebo 3.1%)
upper respiratory tract infection 5.4% (placebo 4.7%)
headache 1.6% (placebo 3.9%)
NCT02139644 · Phase 3 · registry result, not featured evidence
100 mcg once daily
nasopharyngitis 17.9%
NCT02094937 · Phase 3 · registry result, not featured evidence
100/25 mcg once daily
nasopharyngitis 15.6%
NCT02094937 · Phase 3 · registry result, not featured evidence · combination
200/12.5 mcg
upper respiratory tract infection 18%
sinusitis 10.5%
nasopharyngitis 9%
NCT02175771 · Phase 3 · registry result, not featured evidence
200 mcg
upper respiratory tract infection 13.6%
cough 10.4%
nasopharyngitis 10.4%
NCT02175771 · Phase 3 · registry result, not featured evidence
100/12.5 mcg
upper respiratory tract infection 17.5%
nasopharyngitis 12.5%
cough 11.7%
NCT02175771 · Phase 3 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 18.1%
nasopharyngitis 13.4%
sinusitis 11.8%
NCT02175771 · Phase 3 · registry result, not featured evidence
100/50 HFA
headache 15%
nasopharyngitis 9.2%
upper respiratory tract infection 6.4%
NCT00441441 · Phase 3 · registry result, not featured evidence
100 µg OD
cough 8.5% (placebo 5%)
headache 5.9% (placebo 1.7%)
rhinorrhoea 5.1% (placebo 1.7%)
NCT01563029 · Phase 2 · registry result, not featured evidence
50 µg OD
pharyngitis 5.8% (placebo 3.4%)
bronchitis 3.3% (placebo 0.8%)
nasopharyngitis 3.3% (placebo 3.4%)
NCT01563029 · Phase 2 · registry result, not featured evidence
25 µg OD
nasopharyngitis 7.6% (placebo 3.4%)
cough 5.9% (placebo 5%)
oropharyngeal pain 5.1% (placebo 0.8%)
NCT01563029 · Phase 2 · registry result, not featured evidence
12.5 OD
nasopharyngitis 8.8% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
25 OD
nasopharyngitis 7.9% (placebo 7%)
headache 1.8% (placebo 3.5%)
influenza 0% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
6.25 OD
nasopharyngitis 7% (placebo 7%)
headache 5.3% (placebo 3.5%)
influenza 3.5% (placebo 0%)
NCT01573767 · Phase 2 · registry result, not featured evidence
200 mcg
headache 4.7% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
100 mcg
headache 3.7% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
50 mcg
headache 4.7% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
400 mcg
headache 6.5% (placebo 5.7%)
NCT01576718 · Phase 2 · registry result, not featured evidence
100 mcg
upper respiratory tract infection 4.9% (placebo 2.9%)
nasopharyngitis 2.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence
50 mcg
nasopharyngitis 6.7% (placebo 4.8%)
upper respiratory tract infection 2.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
25 mcg
nasopharyngitis 4.8% (placebo 4.8%)
upper respiratory tract infection 1.9% (placebo 2.9%)
NCT01479621 · Phase 2 · registry result, not featured evidence
12.5 mcg
upper respiratory tract infection 6.8% (placebo 2.9%)
nasopharyngitis 3.9% (placebo 4.8%)
NCT01479621 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
  5. eThe assessment timepoint is not available for both results.
  6. fTrial phases differ: Phase 3 versus Phase 2.
  7. gTrial phases differ: Phase 2 versus Phase 4.
  8. hAssessment timepoints differ: 4.14 weeks versus 52 weeks.
  9. iTrial phases differ: Phase 2 versus Phase 3.
  10. jPopulation comparability has not been reviewed for 41 of these studies.
  11. kPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fluticasone Furoate

FEV1 Evening Trough 0.367 vs 0.137 placebo L @ 8wk200 µg OD
absolute change · L
NCT00603382 · Phase 2
show 3 more results
0.341 vs 0.137 placebo L @ 8wk100 µg OD
NCT00603382 · Phase 2
0.266 vs 0.137 placebo L @ 8wk50 µg OD
NCT00603382 · Phase 2
0.239 vs 0.137 placebo L @ 8wk25 µg OD
NCT00603382 · Phase 2
Evening PEF 2.2 vs 0.4 placebo L @ 12wk100 µg OD
absolute change · L
PM PEF, Week 1 to 12
NCT01159912 · Phase 3
Evening PEF 1.5 vs -1.3 placebo L @ 24wk100 µg OD
absolute change · L
PM PEF, Week 1 to 24
NCT01159912 · Phase 3
Morning PEF 13.2 vs 5.7 placebo L @ 12wk100 µg OD
absolute change · L
AM PEF, Week 1 to 12
NCT01159912 · Phase 3
Morning PEF 13.9 vs 5 placebo L @ 24wk100 µg OD
absolute change · L
AM PEF, Week 1 to 24
NCT01159912 · Phase 3
AQLQ Total 0.69 vs 0.45 placebo score @ 12wk100 µg OD
absolute change · score
NCT01159912 · Phase 3
show 4 more results
0.84 vs 0.51 placebo score @ 24wk100 µg OD
NCT01159912 · Phase 3
0.91 vs 0.61 placebo score @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.74 vs 0.66 FF score @ 12wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
0.93 vs 0.88 FF score @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
FEV1 Wm0 24 h 0.499 vs 0.366 FF L @ 12wk200/25 µg OD
absolute change · L
NCT01686633 · Phase 3 · registry result, not featured evidence
show 5 more results
0.513 vs 0.212 placebo L @ 12wk100/25 µg OD
NCT01165138 · Phase 3
0.474 vs 0.366 FF L @ 12wk100/25 µg OD
NCT01686633 · Phase 3 · registry result, not featured evidence
3.303 vs 3.227 placebo L @ 2wk100 µg AM
NCT01808339 · Phase 2 · registry result, not featured evidence
3.332 vs 3.227 placebo L @ 2wk100 µg PM
NCT01808339 · Phase 2 · registry result, not featured evidence
0.464 vs 0.328 FF L @ 24wk200/25 µg OD
NCT01134042 · Phase 3 · combination · Asthma · phase 3
FEV1 Trough 2.714 vs 2.605 placebo L @ 4wk200 µg OD
absolute value · L
NCT00766090 · Phase 2 · registry result, not featured evidence
show 2 more results
2.83 vs 2.462 placebo L @ 12wk100/25 µg OD
NCT01165138 · Phase 3
2.703 vs 2.605 placebo L @ 4wk100 µg BID
NCT00766090 · Phase 2 · registry result, not featured evidence
FEV1 0.284 L @ 24wk200 µg OD
absolute change · L
No placebo or comparator arm
NCT01431950 · Phase 3
show 1 more result
0.208 L @ 24wk100 µg OD
NCT01431950 · Phase 3
Rescue-free 24-h Period 23.1% (n=109) @ 24wk200 µg OD
percent change · % of baseline
No placebo or comparator arm
NCT01431950 · Phase 3
show 1 more result
21.3% (n=108) @ 24wk100 µg OD
NCT01431950 · Phase 3
Evening PEF 7.2 L @ 24wk200 µg OD
absolute change · L
No placebo or comparator arm
NCT01431950 · Phase 3
show 1 more result
5.9 L @ 24wk100 µg OD
NCT01431950 · Phase 3
Morning PEF 13.2 L/min @ 24wk200 µg OD
absolute change · L/min
No placebo or comparator arm
NCT01431950 · Phase 3
show 1 more result
13.4 L/min @ 24wk100 µg OD
NCT01431950 · Phase 3

+ 18 further endpoints in the CSV export.

fluticasone propionate

Max Post-exercise FEV1 Fall 15.02% (n=70) vs 16.71% (n=69) FP @ 2wk100/25 µg QD
percent change · % of baseline
NCT02730351 · Phase 4 · registry result, not featured evidence
show 1 more result
11.9% (n=68) vs 14.05% (n=69) FP @ 2wk100/25 µg QD
NCT02730351 · Phase 4 · registry result, not featured evidence
AM PEF Change L/Min 23.6 vs 9.8 Fluticasone Propionate L @ 52wk250/50 mcg BID
absolute change · L
NCT00452699 · Phase 4 · registry result, not featured evidence
Asthma Symptom Free 27.3 vs 28.6 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence
show 1 more result
37.1 vs 28.5 Fluticasone Propionate % of time @ 52wk250/50 mcg BID
NCT00452699 · Phase 4 · registry result, not featured evidence
Severe Exacerbation Rate Annualized 1.87 vs 2.14 Fluticasone Propionate per year @ 52wk250/50 mcg BID
event rate · per year
NCT00452699 · Phase 4 · registry result, not featured evidence
show 1 more result
2.63 vs 2.73 FP DISKUS per year @ 52wk250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
Morning PEF 10.03 vs 2.24 placebo L @ 12wk200 mcg
absolute change · L
NCT01576718 · Phase 2 · registry result, not featured evidence
show 12 more results
10.29 vs 2.52 placebo L @ 12wk200 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
16.3 vs 9.1 FP L @ 4wk100/50mcg BID
NCT00118716 · Phase 4 · registry result, not featured evidence
14.517 vs 3.591 placebo L @ 12wk100 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
9.34 vs 2.24 placebo L @ 12wk100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
9.39 vs 2.52 placebo L @ 12wk100 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
32 vs 12.3 placebo L @ 12wk50/12.5 mcg BID
NCT02980133 · Phase 3 · registry result, not featured evidence
10.609 vs 3.591 placebo L @ 12wk50 mcg
NCT02139644 · Phase 3 · registry result, not featured evidence
10.48 vs 2.24 placebo L @ 12wk50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
10.85 vs 2.52 placebo L @ 12wk50 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
9.61 vs 2.24 placebo L @ 12wk400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
10.4 vs 2.52 placebo L @ 12wk400 mcg
NCT01576718 · Phase 2 · registry result, not featured evidence
27.7 vs 14.6 FP DISKUS L @ 52wk250/50 mcg BID
NCT00452348 · Phase 4 · registry result, not featured evidence
Asthma Symptom-Free 37.4 vs 28.9 FP DISKUS % of time @ 52wk250/50 mcg BID
percent change · % of time
NCT00452348 · Phase 4 · registry result, not featured evidence
Morning PEF Change L/Min 26.9 vs 19.3 FP L @ 12wk50/100 mcg BD
absolute change · L
NCT00353873 · Phase 4 · registry result, not featured evidence
show 4 more results
27.55 vs 9.26 placebo L @ 12wk100 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
29.58 vs 9.26 placebo L @ 12wk50 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
21.01 vs 9.26 placebo L @ 12wk25 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
30.99 vs 9.26 placebo L @ 12wk12.5 mcg
NCT01479621 · Phase 2 · registry result, not featured evidence
Morning PEF Change L/Min 27.7 vs 18.4 FP L/min @ 12wk50/100 mcg BD
absolute change · L/min
NCT00353873 · Phase 4 · registry result, not featured evidence
show 6 more results
13.7 vs 6.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
14.4 vs 7.4 placebo L/min @ 4wk25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.9 vs 6.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
17 vs 7.4 placebo L/min @ 4wk12.5 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
12 vs 6.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
13.3 vs 7.4 placebo L/min @ 4wk6.25 µg OD
NCT01573767 · Phase 2 · registry result, not featured evidence
Well-Controlled Asthma 43.3% (n=150) vs 40.1% (n=152) FP50/100 mcg BD
event count · % of participants
NCT00353873 · Phase 4 · registry result, not featured evidence · converted to % from 65 Participants as posted
FEV1 Max Fall -9.5% (n=113) vs -12.7% (n=104) FP @ 4wk100/50mcg BID
absolute value · percentage points
NCT00118716 · Phase 4 · registry result, not featured evidence
FEV1 AUC0-4h 0.7 vs 0.3 FP L @ 0wk100/50mcg BID
absolute change · L
NCT00118716 · Phase 4 · registry result, not featured evidence
Rescue-free 59.4 vs 54.7 FP % of time @ 4wk100/50mcg BID
absolute value · % of time
NCT00118716 · Phase 4 · registry result, not featured evidence

+ 19 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone Furoate's landscape · fluticasone propionate's landscape